by Mike Regan | Oct 26, 2022 | Company Analysis, Extract, Macro
Canopy Growth announced a series deals and new share structures to enable Canopy to acquire its US cannabis targets (Wana, Jetty, Acreage, and possibly some of Terrascend) by September 2023. Canopy stock is up 43% on the news and Constellation is up 4%. What are the...
by Mike Regan | Sep 23, 2022 | Comp Table & Market Commentary, Company Analysis, Data & Analysis, Extract, Macro, Thematic Research
As valuations and liquidity have declined since the first quarter 2021 (when the industry raised over $3 billion in equity), debt has become a go-to source of financing. What is the leverage in cannabis? It may be higher than you think. There are also debates on if...
by Mike Regan | Jul 25, 2022 | Company Analysis
Weedmaps is again in the news for servicing unlicensed operators in southern California, this time with delivery apps that either do not have a license, or are illegally renting someone else’s license. See this article by veteran reporter John Schroyer at MJBizDaily...
by Mike Regan | Jun 30, 2022 | Company Analysis, Extract
Canopy Growth (CGC) is issuing between 56.7-78.4 million shares to retire C$255.4 million of its C$600 million convertible note due 2023. The conversion price for this redemption works out to somewhere between US$2.50-3.50, and will be based on the 10 day average...
by Mike Regan | Jun 6, 2022 | Company Analysis
This is a follow-up to the January 16, 2022 article analyzing the contractually mandated dilution due to existing contracts at the Parent Company, which noted the potential signaling by the recipients. The 1Q22 10Q answers that question: This article is for...
by Mike Regan | Jun 6, 2022 | Comp Table & Market Commentary, Company Analysis
You may have heard about the roller coaster direct listing (NOT an IPO) of Bright Green Corp (BGXX), a company that plans to cultivate cannabis for pharmaceutical research under a license from the DEA. This has little read through to the rest of the US cannabis...
